Study finds Ozempic may reverse signs of disease that contributes to 2,000,000 deaths per year
New research has discovered that there could be more effects associated with the drug than just weight loss.
The study, which was published in the New England Journal of Medicine, found that medications that are now being widely used for things such as diabetes and obesity have the potential to offer other health benefits.
This includes treatment for people with liver disease who have seen positive effects from taking semaglutide, which is popularly sold as Wegovy and Ozempic.
The weight loss drugs have been found to effectively treat metabolic dysfunction-associated steatohepatitis (MASH).
MASH is a type of chronic liver disease diagnosed when there is excessive fat build-up in the liver, and at least one metabolic risk factor.
The condition can cause liver scarring, cirrhosis, liver failure and cancer.
Talking about these health benefits, Dr. Celine Gounder, who is a CBS News medical contributor and editor-at-large for public health at KFF Health News, said: 'Almost two-thirds of people had a reduction in liver inflammation related to this fatty liver condition, and over a third had a reduction in liver scarring.'
Speaking about the severity of the condition, Gounder added: 'The life-threatening consequences can be very real.'
However, things could all turn around
Throughout the study, 800 patients were monitored for up to 72 weeks where they documented significant improvements to their liver health while receiving the semaglutide drug.
MASH is a major driver of liver cancer, which contributes to two million deaths per year.
If the drug proves to be a viable treatment for patients with MASH, this could be life changing.
However, despite the fact that study looks promising, Gounder has warned that more research will be needed, specifically longer studies.
She added: 'Seventy-two weeks, that's not very long.'
Examining the results, the study read: 'In part 1 of our trial, patients who received a weekly dose of 2.4 mg of semaglutide had better results regarding steatohepatitis and fibrosis than those who received placebo. Patients in the semaglutide group also had more weight loss.
'Although formal hypothesis tests were not planned or conducted, semaglutide appeared to be associated with improvements in glucometabolic factors and noninvasive markers of liver health. Changes in bodily pain did not differ significantly between the groups.
'The findings were similar regardless of the presence or absence of type 2 diabetes or obesity and regardless of age, sex, or fibrosis stage.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 minutes ago
- Newsweek
How Health Insurance Rates Could Rise in Florida in 2026
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hundreds of thousands of Florida residents could see their health insurance premiums soar by double-digit increases. Fourteen major insurers, including Molina Healthcare, AmeriHealth Caritas, Centene Venture Company and Blue Cross and Blue Shield of Florida, have proposed to increase the premiums for those on Affordable Care Act (ACA)-compliant plans in 2026. Florida is not the only state where such increases are happening, as these health insurance premium increases are "fairly routine," Kosali Simon, a health economist and associate vice provost for Health Sciences at Indiana University Bloomington, told Newsweek. Simon said that while companies proposing premium increases is not new, the "size of the increases insurers are asking for 2026 is larger than usual." Last year, the median proposed increase was 7 percent, and for 2026 that number is currently 18 percent, KFF data shows, with some states, like Florida, seeing "especially high" increases, she said. A spokesperson for Florida Blue told Newsweek it "shares the concerns rising health insurance rates may cause for our members, communities, and other stakeholders." "The premium increases, which are an industry-wide issue, are a necessary response to federal regulatory changes, including the scheduled expiration of premium tax credits at the end of 2025, as well as the rising cost and utilization of medical care and prescription drugs," they added. Newsweek reached out to Molina Healthcare, AmeriHealth Caritas, and Centene Venture Company via email for comment. Why It Matters The rise in health insurance premiums is being broadly driven by a number of factors, including the increased cost and use of health care services. Inflation also plays a role, as well as the cost of health care, labor and increasing demand for medications like GLP-1 drugs like Ozempic and Wegovy, which ramp up prescription drug spending. However, while the increases are not new—insurers have been pushing up the costs of premiums for years—2026 is set to have the largest jump in cost since 2018, KFF data shows. The larger increase in 2026 is due to the fact that next year, enhanced tax credits are set to expire as President Donald Trump has not chosen to renew them. This means that out-of-pocket premium costs for ACA marketplace enrollees will increase by more than 75 percent, meaning many healthier enrollees could drop their coverage, which can, in turn, increase the cost of premiums. File photo: the exterior of the AdventHealth Clermont ER hospital in Clermont, Florida. File photo: the exterior of the AdventHealth Clermont ER hospital in Clermont, Florida. Phelan M. Ebenhack/AP What To Know Former President Joe Biden brought in temporary subsidies for those using ACA marketplaces and extended them to the end of 2025, helping more people have access to health care coverage. As the Trump administration has made no move to renew these subsidies, likely because they come at a steep cost to the taxpayer, they are currently set to expire at the end of the year, meaning premium costs for those using ACA marketplaces will soar. While there is still time for the administration to opt to extend the subsidies, "insurers may not want to take that gamble, and are increasing rates now," Simon said. This is because insurers are likely anticipating who will be buying health insurance. "The young and healthy may not be as likely to buy, and they help keep the costs for the insurers down, so this 'adverse selection' in insurance markets might be what's behind the premium increase," Simon said. In Florida, Molina Healthcare has said it wants to increase rates by just over 40 percent in 2026, which was more than any other plan. This would affect more than 90,000 policyholders. Meanwhile, AmeriHealth Caritas has proposed the second-highest premium increases, at an average price hike of 35 percent, impacting 55,000 policyholders Impacting more than 1.3 million Americans, Centene Venture Company has requested an increase of just over 18 percent. Florida Blue has also proposed to increase premium costs by nearly 27 percent, with some members seeing smaller increases, according to the local news outlet Creative Loafing Tampa Bay. Therefore, while these increases are happening across the country, compared to other states, "Florida seems particularly hard hit," Simon said. What People Are Saying A spokesperson for Florida Blue told Newsweek: "To support our members, we are educating them about the changes and providing personalized support – to help them navigate the enrollment process, understand their coverage options, determine if they qualify for financial assistance, and assist them with staying covered. We are dedicated to making high-quality health care more affordable and accessible to everyone." Mark Pauly, a professor of health care management at Wharton School of the University of Pennsylvania, told Newsweek: "The official government projections are for higher growth in medical spending nationwide, which translates into higher premiums, especially for exchange plans which are not allowed to have a large profit cushion. This high increase is a marked shift in a trend of health spending growth at the same rate as GDP—the share of health spending was the same in 2023 as in 2009." Pauly added: "The trends we are seeing of high claims growth are nationwide. There will be some variation across states but the trend will be common to all." Kosali Simon, a health economist and associate vice provost for Health Sciences at Indiana University Bloomington, told Newsweek: "For the majority of enrollees, especially those with federal premium tax credits, these price increases won't mean they have to pay more, as government subsidies adjust with benchmark plan prices." She added, "For those who don't qualify for subsidies, like many small business owners who buy through the exchange but have higher incomes, it's a problem. Those who have to pay more may drop coverage and become uninsured or have to cut back on other spending." What Happens Next The proposed increases are for the 2026 calendar year, and many are concerned about the impacts they will have on Americans. Pauly said higher premiums "will drive the middle income buyers of exchange insurance to take a chance and go uninsured or switch to a job that has health benefits."
Wall Street Journal
33 minutes ago
- Wall Street Journal
Weight-Loss Drugs Have a Surprising Foe: Fat Activists
In the world of fat activism, the 'O-words'—overweight and obesity—are expressly verboten. That's because advocates and 'fat studies' scholars want to destigmatize and accommodate fatness—their preferred term—and push back against the view that overweight or obese people are somehow abnormal or diseased. Now a third problematic O-word has emerged: Ozempic.
Yahoo
3 hours ago
- Yahoo
‘Life-threatening': Thousands of bogus online pharmacies selling fake Ozempic jabs
Warnings have been issued over fake weight loss jabs that could be 'life-threatening' after thousands of fraudulent online pharmacies were uncovered. Fake versions of Ozempic, a popular brand of weight loss jab, were being sold for as little as £13.70 per dose, along with counterfeit versions of other brands, including Rybelsus and Metformin pills, being offered from 24p. The UK's medicines regulator said taking bogus medications could not only make people ill, but in some cases could be fatal. Researchers from Avast, a cybersecurity brand of the company Gen, who conducted the investigation, warned of the 'dangerous' threat of the global scam involving more than 5,000 fake pharmacy sites this year, which they say are being run by criminal networks. It comes amid the rapid rise of weight-loss medication in the UK – with around 1.5 million people, 4 per cent of households, currently using them. Gen also found fake Viagra, a medicine used to treat erection issues, and unregulated fertility pills being sold. The company said lab tests found no active ingredient in a third of the drugs tested. Andy Morling, deputy director of criminal enforcement at the Medicines and Healthcare products Regulatory Agency (MHRA), told The Independent: 'Buying medicines from illegal suppliers significantly increases the risk of receiving products that are either falsified or not licensed for use in the UK. Products purchased in this way will not meet the MHRA's strict quality and safety standards. 'Medicines obtained from illegally trading sources can not only fail to work, but they can also make you very sick. In some cases, they may contain toxic substances or dangerously high levels of the correct active ingredient, with potentially fatal consequences.' The researchers warned that the 'alarmingly' polished websites, complete with bogus customer service information, detailed product pages, and looked similar to legitimate online pharmacies. But many were detected as fakes because they used AI to create reviews, health blogs, live chat support and manipulated search results. As well as the health implications, the researchers said UK customers risked their details and identity being stolen by the sites. Siggi Stefnission, cyber safety chief technology officer at Gen, warned: 'Purchasing pharmaceuticals from untrusted online retailers is a serious danger, both to individual health and to someone's digital safety. 'From a public health perspective, counterfeit or unregulated drugs can be ineffective or even life-threatening. It's critical that consumers only use licensed, reputable online pharmacies to protect themselves from cybercrime and potential physical harm.' The popularity of weight-loss jabs has soared in the past year, with the NHS's top doctor, Sir Stephen Powis, saying they could soon become among the most commonly used drugs. Both Ozempic and Rybelsus, which have the active ingredient semaglutide, are not licensed as a weight loss treatment. Instead they are designed to treat people with type 2 diabetes but both are sometimes prescribed off-label to treat weight loss. However, popular weight loss jabs Wegovy, which has the same active ingredient, and Mounjaro, which uses the active ingredient tirzepatide, are both licensed in the UK for the treatment of weight loss. Gen explained that criminals are taking advantage of people looking for a fast and discreet way to get high-demand weight loss treatment, among other medications that are often sought quickly, privately, or at a lower cost. Alongside the vast network of more than 5,000 web domains selling the in-demand drugs fraudulently, Gen said, this year alone, it has already blocked 1 million attacks coming from these sites against unsuspecting online shoppers. Laura Wilson, director at Royal Pharmaceutical Society, said fake and illegal online pharmacies 'are a growing threat to patient safety'. She explained that fraudulent medicines may be out of date, substandard or contain 'dangerous' substances. Gen said its team is currently working on testing fake medications to work out what exactly they are made of. The company advised consumers to watch out for low-cost offers for prescription-only drugs, missing contact information, requests for cryptocurrency payments, unsecured checkout processes, and prompts for sensitive personal, medical, or financial data. Novo Nordisk, the company that makes Ozempic and Rybelsus, said it was aware that counterfeit Ozempic products are being sold in the UK and is working with health authorities, including the MHRA, to investigate the 'critical issue'. It advised people to examine packaging and pens closely before using them. Mr Morling said the MHRA is cracking down on the issue of fake medicines and pharmacies, with offenders potentially facing criminal investigation and prosecution. The Independent has approached Pfizer, the company that makes Viagra, for comment.
